Piraye Oflazer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Piraye Oflazer has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Gulshan Yunisova
Department of Neurology Koç University Hospital İstanbul Türkiye
4 shared publications - Ayse Nur Ozdag Acarli
Department of Neurology, Koc University School of Medicine, İstanbul, Turkey
3 shared publications - Hülya Kayserili
Research Center for Translational Medicine (KUTTAM), Koç University School of Medicine (KUSoM), Istanbul, Turkey
3 shared publications - Ayfer Arduç Akçay
Department of Pediatric Neurology Koç University School of Medicine (KUSOM) İstanbul Türkiye
2 shared publications - Emiliano Giardina
Genomic Medicine Laboratory UILDM, IRCCS Santa Lucia Foundation, 00179 Rome, Italy
2 shared publications - Frédérique Magdinier
Marseille Medical Genetics, MMG Aix‐Marseille University INSERM Marseille France
2 shared publications
Latest Publications
- 4 August 2026
- Published by Wiley in Clinical Genetics
- Vol. 110 (5) , 549-557
Hereditary Polyneuropathy Experience of a Tertiary Single‐Center in Türkiye: Beyond the Tip of the Iceberg
Hereditary polyneuropathies (HPPs), including Charcot–Marie–Tooth disease (CMT), represent a genetically and clinically heterogeneous group of disorders. Overlapping phenotypes, genetics, and clinical heterogeneity, and more complex phenotypes mimicking CMT can complicate the diagnosis. This study evaluated the effectiveness of an algorithm‐guided, broad genetic testing strategy in a tertiary neuromuscular center in Türkiye, where recessive disorders are relatively common. Sixty‐seven patients from 63 families referred for suspected HPP (2018–2025) were clinically stratified by phenotype and electrophysiology, and a diagnostic workflow integrating PMP22 MLPA with clinical or whole‐exome sequencing was applied. The overall molecular diagnostic yield was 73% (46/63). PMP22 ‐related neuropathies accounted for 43.5% of all diagnosed cases, with a group‐specific yield of 60%. Among the non‐ PMP22 CMT group, the predominant inheritance pattern was autosomal recessive (70%). Nine novel variants were identified. Two dual molecular diagnoses ( PMP22 / MCCC1 ; MPZ / CRYBB2 ) were established. Importantly, six patients initially labeled as “CMT‐like” harbored non‐CMT disorders, including CYP27A1 ‐, BTD ‐, HEXB ‐, ZFYVE26 ‐, C19ORF12 ‐, and COA7 ‐related diseases—several of which are treatable or actionable. In a population with high genetic heterogeneity and elevated consanguinity, reliance on narrow CMT‐focused panels risks misdiagnosis and may miss therapeutic opportunities. An algorithm‐driven approach integrating PMP22 CNV analysis with exome sequencing substantially improves diagnostic yield, reveals blended or digenic mechanisms, and helps distinguish non‐CMT phenocopies. These findings underscore the importance of comprehensive genomic testing and careful phenotype–genotype correlation in the evaluation of hereditary polyneuropathies.
- 4 August 2026
- Published by Wiley in Clinical Genetics
- Vol. 110 (5) , 549-557
Hereditary Polyneuropathy Experience of a Tertiary Single‐Center in Türkiye: Beyond the Tip of the Iceberg
Hereditary polyneuropathies (HPPs), including Charcot–Marie–Tooth disease (CMT), represent a genetically and clinically heterogeneous group of disorders. Overlapping phenotypes, genetics, and clinical heterogeneity, and more complex phenotypes mimicking CMT can complicate the diagnosis. This study evaluated the effectiveness of an algorithm‐guided, broad genetic testing strategy in a tertiary neuromuscular center in Türkiye, where recessive disorders are relatively common. Sixty‐seven patients from 63 families referred for suspected HPP (2018–2025) were clinically stratified by phenotype and electrophysiology, and a diagnostic workflow integrating PMP22 MLPA with clinical or whole‐exome sequencing was applied. The overall molecular diagnostic yield was 73% (46/63). PMP22 ‐related neuropathies accounted for 43.5% of all diagnosed cases, with a group‐specific yield of 60%. Among the non‐ PMP22 CMT group, the predominant inheritance pattern was autosomal recessive (70%). Nine novel variants were identified. Two dual molecular diagnoses ( PMP22 / MCCC1 ; MPZ / CRYBB2 ) were established. Importantly, six patients initially labeled as “CMT‐like” harbored non‐CMT disorders, including CYP27A1 ‐, BTD ‐, HEXB ‐, ZFYVE26 ‐, C19ORF12 ‐, and COA7 ‐related diseases—several of which are treatable or actionable. In a population with high genetic heterogeneity and elevated consanguinity, reliance on narrow CMT‐focused panels risks misdiagnosis and may miss therapeutic opportunities. An algorithm‐driven approach integrating PMP22 CNV analysis with exome sequencing substantially improves diagnostic yield, reveals blended or digenic mechanisms, and helps distinguish non‐CMT phenocopies. These findings underscore the importance of comprehensive genomic testing and careful phenotype–genotype correlation in the evaluation of hereditary polyneuropathies.
- 15 April 2026
- Published by Elsevier in Neuromuscular Disorders
- Vol. 63, 106434
Bridging past and future: the evolution of genetic diagnosis in FSHD and the role of emerging technologies in a globalized framework
- 15 April 2026
- Published by Elsevier in Neuromuscular Disorders
- Vol. 63, 106434
Bridging past and future: the evolution of genetic diagnosis in FSHD and the role of emerging technologies in a globalized framework
- 26 December 2025
- Published by Wiley in Clinical Genetics
- Vol. 109 (5) , 889-903
Congenital Myasthenic Syndrome: Long‐Term Outcomes up to 60 Years, Molecular Characterization, and Eight Novel Variants
Congenital myasthenic syndrome (CMS) refers to a rare heterogeneous group of hereditary disorders characterized by fatigue and muscle weakness due to impairment in neuromuscular transmission. A total of 40 genes have been identified in the pathogenesis of CMSs. The study assessed 22 patients (14 females and 8 males) with CMS of childhood onset with their phenotypes and genotypes. Genetic analysis revealed variations in the following eight genes: CHRNE , DOK7 , GFPT1 , COLQ , SLC25A1 , CHAT , MUSK , and MYO9A. Eight novel variations were detected involving SLC25A1 , MUSK , DOK7 , GFPT1 , and CHRNE . The median age was 14 years (range: 0.5–67 years). The median age of onset of symptoms was 8 months (range: 0–16 years). The longest time after the onset of symptoms was 62 years. The most common initial symptoms were weakness of extremities ( n = 9) and ptosis ( n = 8). Respiratory symptoms were present in 11 patients (50%), which showed progression, multiphasic disease course, and amelioration in 45.4%, 18.1%, and 36.3% of patients, respectively. Motor symptoms showed a progressive worsening in 68.1%, stationary course in 13.6%, multiphasic disease course in 13.6%, and amelioration in 4.5% of patients. Thanks to next‐generation sequencing, diagnoses of CMS have been increasing over the recent years; so has the number of novel variants.
- 26 December 2025
- Published by Wiley in Clinical Genetics
- Vol. 109 (5) , 889-903
Congenital Myasthenic Syndrome: Long‐Term Outcomes up to 60 Years, Molecular Characterization, and Eight Novel Variants
Congenital myasthenic syndrome (CMS) refers to a rare heterogeneous group of hereditary disorders characterized by fatigue and muscle weakness due to impairment in neuromuscular transmission. A total of 40 genes have been identified in the pathogenesis of CMSs. The study assessed 22 patients (14 females and 8 males) with CMS of childhood onset with their phenotypes and genotypes. Genetic analysis revealed variations in the following eight genes: CHRNE , DOK7 , GFPT1 , COLQ , SLC25A1 , CHAT , MUSK , and MYO9A. Eight novel variations were detected involving SLC25A1 , MUSK , DOK7 , GFPT1 , and CHRNE . The median age was 14 years (range: 0.5–67 years). The median age of onset of symptoms was 8 months (range: 0–16 years). The longest time after the onset of symptoms was 62 years. The most common initial symptoms were weakness of extremities ( n = 9) and ptosis ( n = 8). Respiratory symptoms were present in 11 patients (50%), which showed progression, multiphasic disease course, and amelioration in 45.4%, 18.1%, and 36.3% of patients, respectively. Motor symptoms showed a progressive worsening in 68.1%, stationary course in 13.6%, multiphasic disease course in 13.6%, and amelioration in 4.5% of patients. Thanks to next‐generation sequencing, diagnoses of CMS have been increasing over the recent years; so has the number of novel variants.
- Open Access
- 29 April 2024
- Published by Wiley in Clinical Genetics
- Vol. 106 (1) , 13-26
Best practice guidelines on genetic diagnostics of facioscapulohumeral muscular dystrophy: Update of the 2012 guidelines
The gold standard for facioscapulohumeral muscular dystrophy (FSHD) genetic diagnostic procedures was published in 2012. With the increasing complexity of the genetics of FSHD1 and 2, the increase of genetic testing centers, and the start of clinical trials for FSHD, it is crucial to provide an update on our knowledge of the genetic features of the FSHD loci and renew the international consensus on the molecular testing recommendations. To this end, members of the FSHD European Trial Network summarized the evidence presented during the 2022 ENMC meeting on Genetic diagnosis, clinical outcome measures, and biomarkers. The working group additionally invited genetic and clinical experts from the USA, India, Japan, Australia, South‐Africa, and Brazil to provide a global perspective. Six virtual meetings were organized to reach consensus on the minimal requirements for genetic confirmation of FSHD1 and FSHD2. Here, we present the clinical and genetic features of FSHD, specific features of FSHD1 and FSHD2, pros and cons of established and new technologies (Southern blot in combination with either linear or pulsed‐field gel electrophoresis, molecular combing, optical genome mapping, FSHD2 methylation analysis and FSHD2 genotyping), the possibilities and challenges of prenatal testing, including pre‐implantation genetic testing, and the minimal requirements and recommendations for genetic confirmation of FSHD1 and FSHD2. This consensus is expected to contribute to current clinical management and trial‐readiness for FSHD.
- 29 April 2024
- Published by Wiley in Clinical Genetics
- Vol. 106 (1) , 13-26
Open AccessBest practice guidelines on genetic diagnostics of facioscapulohumeral muscular dystrophy: Update of the 2012 guidelines
The gold standard for facioscapulohumeral muscular dystrophy (FSHD) genetic diagnostic procedures was published in 2012. With the increasing complexity of the genetics of FSHD1 and 2, the increase of genetic testing centers, and the start of clinical trials for FSHD, it is crucial to provide an update on our knowledge of the genetic features of the FSHD loci and renew the international consensus on the molecular testing recommendations. To this end, members of the FSHD European Trial Network summarized the evidence presented during the 2022 ENMC meeting on Genetic diagnosis, clinical outcome measures, and biomarkers. The working group additionally invited genetic and clinical experts from the USA, India, Japan, Australia, South‐Africa, and Brazil to provide a global perspective. Six virtual meetings were organized to reach consensus on the minimal requirements for genetic confirmation of FSHD1 and FSHD2. Here, we present the clinical and genetic features of FSHD, specific features of FSHD1 and FSHD2, pros and cons of established and new technologies (Southern blot in combination with either linear or pulsed‐field gel electrophoresis, molecular combing, optical genome mapping, FSHD2 methylation analysis and FSHD2 genotyping), the possibilities and challenges of prenatal testing, including pre‐implantation genetic testing, and the minimal requirements and recommendations for genetic confirmation of FSHD1 and FSHD2. This consensus is expected to contribute to current clinical management and trial‐readiness for FSHD.
- Open Access
- 27 February 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
SNUPN deficiency causes a recessive muscular dystrophy due to RNA mis-splicing and ECM dysregulation
SNURPORTIN-1, encoded by SNUPN, plays a central role in the nuclear import of spliceosomal small nuclear ribonucleoproteins. However, its physiological function remains unexplored. In this study, we investigate 18 children from 15 unrelated families who present with atypical muscular dystrophy and neurological defects. Nine hypomorphic SNUPN biallelic variants, predominantly clustered in the last coding exon, are ascertained to segregate with the disease. We demonstrate that mutant SPN1 failed to oligomerize leading to cytoplasmic aggregation in patients’ primary fibroblasts and CRISPR/Cas9-mediated mutant cell lines. Additionally, mutant nuclei exhibit defective spliceosomal maturation and breakdown of Cajal bodies. Transcriptome analyses reveal splicing and mRNA expression dysregulation, particularly in sarcolemmal components, causing disruption of cytoskeletal organization in mutant cells and patient muscle tissues. Our findings establish SNUPN deficiency as the genetic etiology of a previously unrecognized subtype of muscular dystrophy and provide robust evidence of the role of SPN1 for muscle homeostasis.
- 27 February 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
Open AccessSNUPN deficiency causes a recessive muscular dystrophy due to RNA mis-splicing and ECM dysregulation
SNURPORTIN-1, encoded by SNUPN, plays a central role in the nuclear import of spliceosomal small nuclear ribonucleoproteins. However, its physiological function remains unexplored. In this study, we investigate 18 children from 15 unrelated families who present with atypical muscular dystrophy and neurological defects. Nine hypomorphic SNUPN biallelic variants, predominantly clustered in the last coding exon, are ascertained to segregate with the disease. We demonstrate that mutant SPN1 failed to oligomerize leading to cytoplasmic aggregation in patients’ primary fibroblasts and CRISPR/Cas9-mediated mutant cell lines. Additionally, mutant nuclei exhibit defective spliceosomal maturation and breakdown of Cajal bodies. Transcriptome analyses reveal splicing and mRNA expression dysregulation, particularly in sarcolemmal components, causing disruption of cytoskeletal organization in mutant cells and patient muscle tissues. Our findings establish SNUPN deficiency as the genetic etiology of a previously unrecognized subtype of muscular dystrophy and provide robust evidence of the role of SPN1 for muscle homeostasis.
- Open Access
- 1 March 2023
- Published by Springer Nature in Journal of Rare Diseases
- Vol. 2 (1) , 1-4
Acute intermittent porphyria and spinal muscular atrophy: two rare diseases seen in one patient
Porphyrias are a cluster of inherited metabolic diseases. Acute intermittent porphyria (AIP) is inherited autosomal dominantly that presents with multi-systemic symptoms and acute repetitive attacks in any age of lifespan. Spinal muscular atrophy (SMA) is a motor neuron disease that is autosomal recessively inherited and seen with a relatively higher incidence in Turkey. In this case report, we discuss a 27-year-old male with gait problems and fatigue. Here, we report a familial heterozygous mutation in hydroxymethylbilane synthase (HMBS) gene together with homozygous deletion in the survival motor neuron 1 (SMN1) gene in a Turkish patient.
- 1 March 2023
- Published by Springer Nature in Journal of Rare Diseases
- Vol. 2 (1) , 1-4
Open AccessAcute intermittent porphyria and spinal muscular atrophy: two rare diseases seen in one patient
Porphyrias are a cluster of inherited metabolic diseases. Acute intermittent porphyria (AIP) is inherited autosomal dominantly that presents with multi-systemic symptoms and acute repetitive attacks in any age of lifespan. Spinal muscular atrophy (SMA) is a motor neuron disease that is autosomal recessively inherited and seen with a relatively higher incidence in Turkey. In this case report, we discuss a 27-year-old male with gait problems and fatigue. Here, we report a familial heterozygous mutation in hydroxymethylbilane synthase (HMBS) gene together with homozygous deletion in the survival motor neuron 1 (SMN1) gene in a Turkish patient.
- 15 July 2022
- Published by Elsevier in Respiratory Medicine
- Vol. 200, 106931
The clinical use of impulse oscillometry in neuromuscular diseases
- 15 July 2022
- Published by Elsevier in Respiratory Medicine
- Vol. 200, 106931
The clinical use of impulse oscillometry in neuromuscular diseases
- Open Access
- 1 December 2020
- Vol. 39 (4) , 302-306
Giant cell myositis and myocarditis revisited.
Giant cell myositis (GCMm) and giant cell myocarditis (GCMc) are two rare autoimmune conditions. Among these, GCMc is a life-threatening disease with a 1-year mortality rate of 70%. Lethal ventricular arrhythmias, rapid evolution to heart failure and sudden death risk makes GCMc an emergency condition. It is thought to be mediated by T-cells and characterized by the presence of myofiber necrosis and giant cells in biopsies. Most commonly co-manifesting conditions with GCMm and/or GCMc are thymoma, myasthenia gravis and orbital myositis, all of which are treatable. As suspicion is the key approach in diagnosis, the physician following patients with thymoma with or without myasthenia gravis and with orbital myositis should always be alert. The fatal nature of GCMc associated with these relatively benign diseases deserves a special emergency attention with prompt institution of combined immunosuppressive treatment and very early inclusion of heart failure teams.
- 1 December 2020
- Vol. 39 (4) , 302-306
Open AccessGiant cell myositis and myocarditis revisited.
Giant cell myositis (GCMm) and giant cell myocarditis (GCMc) are two rare autoimmune conditions. Among these, GCMc is a life-threatening disease with a 1-year mortality rate of 70%. Lethal ventricular arrhythmias, rapid evolution to heart failure and sudden death risk makes GCMc an emergency condition. It is thought to be mediated by T-cells and characterized by the presence of myofiber necrosis and giant cells in biopsies. Most commonly co-manifesting conditions with GCMm and/or GCMc are thymoma, myasthenia gravis and orbital myositis, all of which are treatable. As suspicion is the key approach in diagnosis, the physician following patients with thymoma with or without myasthenia gravis and with orbital myositis should always be alert. The fatal nature of GCMc associated with these relatively benign diseases deserves a special emergency attention with prompt institution of combined immunosuppressive treatment and very early inclusion of heart failure teams.
- 25 October 2019
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 102 (3) , 237-244
Functional Outcomes and Complications Following Scapulothoracic Arthrodesis in Patients with Facioscapulohumeral Dystrophy
Background: Facioscapulohumeral dystrophy (FSHD) is an autosomal-dominant myopathy characterized by facial and shoulder girdle muscle weakness with scapular winging. Scapulothoracic arthrodesis is a successful treatment approach for patients with <90° of shoulder elevation. The purpose of the present study was to assess functional outcomes and complications following scapulothoracic arthrodesis in patients with FSHD. Methods: We retrospectively reviewed the records of 40 patients (64 shoulders) in whom scapulothoracic arthrodesis was performed. To achieve fusion, multiple multifilament cables were used together with autologous bone and allograft bone. Preoperative and postoperative shoulder elevation and abduction; Disabilities of the Arm, Shoulder and Hand (Quick version, qDASH) scores; and pulmonary function were compared. Recorded complications were classified as pulmonary or scapular. Results: The mean age of the patients at the time of the operation was 25.4 years (range, 15 to 60 years), and the mean duration of follow-up was 71.2 months (range, 12 to 185 months). When the preoperative values were compared with those at the latest follow-up, significant improvement was noted in terms of elevation (from a mean [and standard deviation] of 60.6° ± 17.2° to 123.7° ± 26.7°; p < 0.001), abduction (from 52.7° ± 15.8° to 98.8° ± 20.3°; p < 0.001), and qDASH scores (from 34.7 ± 11.4 to 13.3 ± 13.1; p < 0.001). The overall complication rate was 26.6%. There were 7 pulmonary complications (4 pneumothoraxes, 2 pleural effusions, and 1 major atelectasis), and 5 chest tube placements were required. Ten complications (including 3 rib fractures, 1 brachial plexus palsy, 2 cases of implant irritation, 2 nonunions, 1 delayed union, and 1 scapular fracture) were related to the scapular fixation, and 7 revision procedures were required. Scapulothoracic fusion was achieved in all patients but 1, who had a scapular fracture. Pulmonary function tests were performed for 19 patients, and no difference was observed between preoperative and postoperative results. Conclusions: Scapulothoracic arthrodesis with use of multifilament cables is a successful surgical technique with high fusion rates and low morbidity. Pulmonary complications are common but resolve with careful attention. Level of Evidence: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.
- 25 October 2019
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 102 (3) , 237-244
Functional Outcomes and Complications Following Scapulothoracic Arthrodesis in Patients with Facioscapulohumeral Dystrophy
Background: Facioscapulohumeral dystrophy (FSHD) is an autosomal-dominant myopathy characterized by facial and shoulder girdle muscle weakness with scapular winging. Scapulothoracic arthrodesis is a successful treatment approach for patients with <90° of shoulder elevation. The purpose of the present study was to assess functional outcomes and complications following scapulothoracic arthrodesis in patients with FSHD. Methods: We retrospectively reviewed the records of 40 patients (64 shoulders) in whom scapulothoracic arthrodesis was performed. To achieve fusion, multiple multifilament cables were used together with autologous bone and allograft bone. Preoperative and postoperative shoulder elevation and abduction; Disabilities of the Arm, Shoulder and Hand (Quick version, qDASH) scores; and pulmonary function were compared. Recorded complications were classified as pulmonary or scapular. Results: The mean age of the patients at the time of the operation was 25.4 years (range, 15 to 60 years), and the mean duration of follow-up was 71.2 months (range, 12 to 185 months). When the preoperative values were compared with those at the latest follow-up, significant improvement was noted in terms of elevation (from a mean [and standard deviation] of 60.6° ± 17.2° to 123.7° ± 26.7°; p < 0.001), abduction (from 52.7° ± 15.8° to 98.8° ± 20.3°; p < 0.001), and qDASH scores (from 34.7 ± 11.4 to 13.3 ± 13.1; p < 0.001). The overall complication rate was 26.6%. There were 7 pulmonary complications (4 pneumothoraxes, 2 pleural effusions, and 1 major atelectasis), and 5 chest tube placements were required. Ten complications (including 3 rib fractures, 1 brachial plexus palsy, 2 cases of implant irritation, 2 nonunions, 1 delayed union, and 1 scapular fracture) were related to the scapular fixation, and 7 revision procedures were required. Scapulothoracic fusion was achieved in all patients but 1, who had a scapular fracture. Pulmonary function tests were performed for 19 patients, and no difference was observed between preoperative and postoperative results. Conclusions: Scapulothoracic arthrodesis with use of multifilament cables is a successful surgical technique with high fusion rates and low morbidity. Pulmonary complications are common but resolve with careful attention. Level of Evidence: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.